| Schedule of asset and income by segment |
The following tables summarize the Company's total
current and non-current assets and current and non-current liabilities as of June 30, 2026, and December 31, 2025, on a segmented basis:
| | |
Biopharmaceutical | | |
Total | |
| | |
$ | | |
$ | |
| Current assets | |
| 9,961,395 | | |
| 9,961,395 | |
| Non-current assets | |
| 4,430,490 | | |
| 4,430,490 | |
| Current liabilities | |
| 8,297,670 | | |
| 8,297,670 | |
| | |
Biopharmaceutical | | |
Total | |
| | |
$ | | |
$ | |
| Current assets | |
| 6,478,353 | | |
| 6,478,353 | |
| Non-current assets | |
| 4,682,556 | | |
| 4,682,556 | |
| Current liabilities | |
| 6,058,294 | | |
| 6,058,294 | |
| | |
For the six months ended June 30, 2026 | |
| | |
Biopharmaceutical | | |
Strategic Investments | | |
Total | |
| | |
$ | | |
$ | | |
$ | |
| Interest expense (income) | |
| 52,116 | | |
| (510 | ) | |
| 51,606 | |
| Total operating expenses | |
| 5,259,659 | | |
| 236 | | |
| 5,259,895 | |
| Net (loss) income | |
| (16,846,774 | ) | |
| 274 | | |
| (16,846,500 | ) |
| | |
For the three months ended June 30, 2026 | |
| | |
Biopharmaceutical | | |
Strategic Investments | | |
Total | |
| | |
$ | | |
$ | | |
$ | |
| Interest expense | |
| 42,537 | | |
| 7 | | |
| 42,544 | |
| Total operating expenses | |
| 2,293,488 | | |
| 102 | | |
| 2,293,590 | |
| Net (loss) | |
| (3,092,826 | ) | |
| (110 | ) | |
| (3,092,936 | ) |
| | |
For the six months ended June 30, 2025 | |
| | |
Biopharmaceutical | | |
Strategic Investments | | |
Total | |
| | |
$ | | |
$ | | |
$ | |
| Interest (income) | |
| (24,727 | ) | |
| (133,222 | ) | |
| (157,949 | ) |
| Total operating expenses | |
| 8,250,414 | | |
| 448 | | |
| 8,250,862 | |
| Net (loss) income | |
| (18,638,981 | ) | |
| 132,773 | | |
| (18,506,208 | ) |
| | |
For
the three months ended June 30, 2025 | |
| | |
Biopharmaceutical | | |
Strategic Investments | | |
Total | |
| | |
$ | | |
$ | | |
$ | |
| Interest (income) | |
| (22,144 | ) | |
| (68,589 | ) | |
| (90,733 | ) |
| Total operating expenses | |
| 4,853,313 | | |
| 126 | | |
| 4,853,439 | |
| Net (loss) income | |
| (9,834,790 | ) | |
| 68,463 | | |
| (9,766,327 | ) |
|